Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates

Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates

Adeno-associated virus (AAV) vector gene therapy is a promising treatment for a variety of genetic diseases, including hemophilia. Systemic administration of AAV vectors is associated with a cytotoxic immune response triggered against AAV capsid proteins, which if untreated can result in loss of tra...

Full description

Bibliographic Details
Main Authors: Benjamin J. Samelson-Jones, Jonathan D. Finn, Patricia Favaro, J. Fraser Wright, Valder R. Arruda
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
AAV
gene therapy
gene transfer
immunogenecity
nonhuman primates
transgene immunogenecity
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050120300887

Internet

http://www.sciencedirect.com/science/article/pii/S2329050120300887

Similar Items